Patrick W. McLaughlin, MD, presented “The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer” during the 24th Annual Southwest Prostate Cancer Symposium on April 11, 2019 in Scottsdale, Arizona.
How to cite: McLaughlin, Patrick W. “The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer” April 11, 2019. Accessed Apr 2024. https://dev.grandroundsinurology.com/the-staggering-benefit-of-psa-screening-in-potentially-lethal-prostate-cancer/
The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer – Summary:
Patrick W. McLaughlin, MD, discusses the limitations of evidence that provide the basis for the United States Preventive Services Task Force’s (USPSTF’s) negative gradings for PSA screening. He argues that in the modern era, with the currently-available curative therapy for most lethal prostate cancers, intensive screening can allow early enough detection to provide patients opportunities for a cure.
About the Southwest Prostate Cancer Symposium
The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. McLaughlin presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment-related devices on site. Please visit this page in order to register for future SPCS meetings.
